|Description||EGF816 mesylate is the mesylate salt of EGF816 which is a covalent mutant-selective EGFR inhibitor and potently inhibits the T790M.|
|Appearance||White to off-white solid|
|Solubility||Soluble in DMSO|
|Storage||Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -46℃ for long term (months to years).|
|Shelf Life||2 years|
EGF816, also called as Nazartinib, a covalent mutant-selective EGFR inhibitor and potently inhibits the T790M resistance mutation while sparing wild-type EGFR. ...
Tarloxotinib bromide, a pyridopyrimidine derivative, has been found to be a EGFR tyrosine kinase inhibitor precursor and could probably be effective in antineop...
AG 99, an EGF receptor tyrosine kinase inhibitor, has been found to show activities in diagnosis, prevention and treatment of cancer.
EGF816 mesylate is the mesylate salt of EGF816 which is a covalent mutant-selective EGFR inhibitor and potently inhibits the T790M.
TAK-285 is a novel dual erbB protein kinase inhibitor that specifically targets human epidermal growth factor receptor (EGFR) and HER2. Methods: TAK-285 is curr...
WZ8040 is a novel mutant-selective irreversible EGFRT790M inhibitor with potential anticancer activity. WZ8040 is about 30-fold more potent against EGFR T790M, ...
TPC-064 is a novel mutant-selective inhibitor of EGFR, which plays a role in NSCLC and therefore becomes a key target for cancer therapy. TPC-064 can selectivel...
AG 1478 hydrochloride
The hydrochloride salt form of AG 1478, which has been found to be an epidermal growth factor receptor tyrosine kinase inhibitor.
Afatinib Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, res...
PD153035 is a ATP-competitive EGFR inhibitor with an IC50 and Ki of 25 and 6 pM. PD153035 effectively blocks the enhancement of mitogenesis, induction of early ...
Lazertinib, also known as YH-25448 and GNS-1480, is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible 3rd gene...
BMS 599626 dihydrochloride is a potent and selective EGFR and ErbB2 inhibitor (IC50 = 22 nM and 32 nM, respectively), and also inhibits HER4 (IC50 = 190 nM). BM...
Varlitinib, also known as ARRY-543, is an orally bioavailable inhibitor of the epidermal growth factor receptor family with potential antineoplastic activity. V...
RG13022, a non-phenolic tyrphostin analog, is an epidermal growth factor (EGF) receptor tyrosine kinase inhibitor with potential antiproliferative effect.
BIBU 1361 dihydrochloride
BIBU 1361 dihydrochloride is an inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase (IC50 = 3 nM) with ~ 100-fold lower potency than ErbB2 (IC5...
Canertinib dihydrochloride is the hydrochloride salt of an orally bio-available quinazoline with potential antineoplastic and radiosensitizing activities. Caner...
AG-1557 is an inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase.
HDS 029 is a potent inhibitor of the ErbB receptor family including EGFR, ErbB2 and ErbB4 (IC50 = 0.3, 0.5 and 1.1 nM for ErbB1 (EGFR), ErbB4 and ErbB2, respect...
AZ5104 is a potent EGFR inhibitor and a derivative of AZD 9291. AZ5104 exhibits reduced selectivity against wild-type EGFR but five-fold potentcy compared to AZ...
Irbinitinib,also known as ARRY-380 and ONT-380, is an orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also...